ImmunityBio Reports First European Patients Treated With Anktiva Plus BCG
ImmunityBio says the first patients in Europe have been treated with Anktiva plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.
ImmunityBio says the first patients in Europe have been treated with Anktiva plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.